History and Origins

The technology was conceptualized by current CEO in the mid-90’s at the request of an inquirer who became a collaborator/co-inventor. The state of transdermal art was analyzed and key parameters controlling transdermal flux identified and system to modulate these characteristics composed of GRAS-listed substances developed.

Intellectual property situation

The Company’s technology is protected by three (3) broad patents in the United States and twenty (20) additional patents issued in the EU, Canada, Mexico and Japan.

Organization

The company was founded in 2012 and is located in Southeastern US.

It has 5 FTE and recently engaged investment banking to assist in the capital raise. Management team has long history in pharmaceutical sector.

Key Takeaways

The company can provide a safer and faster delivery of drugs combined with a billion-dollar market potential at a low incremental cost.

In addition to providing immediate delivery, it provides a more direct means to deliver a much smaller, but equally effective dose of drugs.

Management has very good understanding of the pharma market and should be able to secure licensing and partnerships.